• TORONTO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine. (valleycentral.com)
  • Following the success of the 3rd Annual Psychedelic Therapeutics and Drug Development Conference in 2023, we're thrilled to be hosting the 4th Annual event. (pharmamanufacturing.com)
  • Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA - September 19, 2023 - ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and inflammatory diseases, today announced the appointment of Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development. (wowktv.com)
  • REHOVOT and RAMAT GAN , Israel , Nov. 21, 2023 /PRNewswire/ -- Skip Therapeutics (" Skip "), developer of computational platform for design of Antisense Oligonucleotide (ASO) based therapies and Sheba Medical Center (" Sheba "), one of the leading medical centers in the world, announced today that they have entered a collaboration for the development of ASO-based treatments for rare genetic diseases. (ktla.com)
  • NEW HAVEN, Conn., March 09, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the fourth quarter and full year ended Dec. 31, 2022 and provided an update on key strategic initiatives. (globenewswire.com)
  • Skip Therapeutics employs its proprietary bioinformatic engine to identify the most promising ASO-based molecular strategy for treatment of each patient sub-population based on their specific mutations. (ktla.com)
  • Dr. Dan Dominissini , deputy director of the Center for Cancer Research and director of the Hematology Laboratory at Sheba Medical Center, stated, "We are delighted to collaborate with Skip Therapeutics for the development of cutting edge ASO-based therapies for genetic diseases. (ktla.com)
  • Skip Therapeutics' novel computational engine will enables us not only to determine the most appropriate therapeutic design for a given genetic disease, but also to directly identify treatable patient populations, thereby maximizing efficiency and minimizing costs. (ktla.com)
  • Vancouver, BC, Canada, July 5 th , 2022 - Defence Therapeutics Inc. (" Defence " or the " Company "), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to provide an update on its ADC programs in development using Defence's Accum TM , including key in vivo studies with worldwide collaborators. (pharmiweb.com)
  • SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today that results of nonclinical studies of two formulations of CD101, a novel echinocandin, will be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the International Society of Chemotherapy (ICC) joint meeting in San Diego, September 17-21, 2015. (biospace.com)
  • Glycosylation - the attachment of sugars to proteins - plays a critical role in both cellular function and in the development of therapeutics, like vaccines. (northwestern.edu)
  • Glycosylation is important in the development of protein medicines, which include everything from anti-cancer drugs like Herceptin to flu and tetanus vaccines. (northwestern.edu)
  • Future works will use other pathways developed in this paper to create glycosylated protein vaccines and therapeutics that can target certain areas within the body. (northwestern.edu)
  • Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. (pharmiweb.com)
  • Tim then goes on to explore the future of mRNA vaccines and other RNA therapeutics. (mendelspod.com)
  • ABL, Inc. is a global contract research and manufacturing organization dedicated to advancing therapeutics, vaccines and other biological products. (ablinc.com)
  • ABL maintains global GMP facilities meeting U.S. and European regulatory standards, providing manufacturing capabilities for the development and production of virus-based oncolytic therapies, gene therapies and viral vaccines. (ablinc.com)
  • Prior to joining Novartis, she was Laboratory Head of Process Development and Analytics at Cytos Biotechnology, where she led a team of scientists and engineers responsible for process development and production of clinical material for various product candidates. (wowktv.com)
  • ABL, as an awardee of the IDIQ contract pool will provide NINDS current Good Manufacturing Practices (cGMP) manufacturing and Good Laboratory Practice (GLP) nonclinical (preclinical) services to support translational development of therapeutic biotechnology (biologics) products of various modalities for NIH's drug discovery and development programs. (ablinc.com)
  • Aptevo Therapeutics Inc (Aptevo) is a clinical-stage biotechnology company that develops and commercializes oncology and hematology therapeutics. (researchandmarkets.com)
  • (SOUTH PLAINFIELD, NJ and BETHESDA, Md.) -- PTC Therapeutics, Inc. and Cystic Fibrosis Foundation Therapeutics, Inc. , the nonprofit affiliate of the Cystic Fibrosis Foundation, today announced the expansion of an existing research project to support development of PTC124, the PTC's new investigational oral drug for the treatment of cystic fibrosis caused by nonsense mutations. (cff.org)
  • We are pleased to expand our program with PTC Therapeutics on the development of the therapy PTC124," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. (cff.org)
  • An official American Thoracic Society workshop report: chemical inhalational disasters - biology of lung injury, development of novel therapeutics, and medical preparedness. (cdc.gov)
  • RP and its molecular components may thus constitute valuable research targets in the development of novel therapeutics for stress-related psychological disorders. (lu.se)
  • The main types of RNA therapeutics are those based on messenger RNA (mRNA), antisense RNA (asRNA), RNA interference (RNAi), and RNA aptamers. (wikipedia.org)
  • Of the four types, mRNA-based therapy is the only type which is based on triggering synthesis of proteins within cells, making it particularly useful in vaccine development. (wikipedia.org)
  • However, mRNA therapeutics do not need to enter into the nucleus to be functional since it will be translated immediately once it has reached to the cytoplasm. (wikipedia.org)
  • Allergan will make Molecular Partners a combined up-front payment of $62.5 million as part of two new agreements centered on the discovery, development, and commercialization of DARPin® (Designed Ankyrin Repeat Protein) therapeutics for treating serious ophthalmic disorders. (genengnews.com)
  • Weston Kightlinger, a PhD student in the Jewett lab, developed a new approach to build, test, and assess sets of enzymes that can modularly build sugars for protein therapeutics. (northwestern.edu)
  • We are excited to have her join the team and lead our CMC and technical development efforts to develop and manufacture novel protein- and antibody-based therapies," said Steve Coats, PhD, Chief Development Officer at ImmunOs. (wowktv.com)
  • Recent advancements in RNA-therapeutics offer an expanded molecular toolkit that can be deployed rapidly and at relatively low costs to restore protein function of mutated genes. (ktla.com)
  • These specific aspects are reviewed in this article, with separate attention being paid to small organic molecules and protein therapeutics. (snmjournals.org)
  • Although microdosing has been associated predominantly with small organic molecules and site-specific labeling, there is growing interest in applying the concept to protein therapeutics and in using some of the exclusive properties of proteins for nuclear imaging purposes. (snmjournals.org)
  • PTC124 is currently in Phase 2b development in DMD with the goal of demonstrating that increasing functional protein levels in patients with nonsense-mutation-mediated genetic disorders may provide clinical benefits. (cff.org)
  • This is because protein and peptide therapeutics require parenteral (delivery by the intravenous route) administration, which serves as a barrier or deterrent to adherence to medication regimes. (azolifesciences.com)
  • Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. (biospace.com)
  • The Technology Development group at Life Edit discovers new genome editing systems and establishes new editing capabilities and optimizes them to support efforts developing curative gene editing therapies and gene edited cell therapies. (biospace.com)
  • The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. (biospace.com)
  • In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies. (biospace.com)
  • I am excited to use my expertise in the development and manufacturing of a broad range of novel biologics to help advance the Company´s pipeline of innovative HLA-based therapies, which are designed to address both the adaptive and innate immune systems. (wowktv.com)
  • Research applications may include the development of new chemical entities, new lead compounds, repurposed marketed medications, new formulations of existing medications, new behavioral therapies, therapeutic devices, and digital therapeutics. (nih.gov)
  • Kronos Bio , a Silicon Valley-based clinical-stage biopharmaceutical startup dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets, today announced private financing of approximately $155 million of convertible notes, with $148 million in funding received to date and the remaining $7 million to be funded by mid-September pursuant to binding commitments. (techstartups.com)
  • The Institut de Recherche en Cancérologie de Montpellier (IRCM), an internationally recognized institute for its translational research and expertise's in immunotherapy and radiotherapy, is currently performing in vivo studies using Accum TM with radio-immuno-therapeutic conjugates. (pharmiweb.com)
  • The purpose of this funding opportunity announcement (FOA) is to support the development of new therapeutic approaches for individuals with Opioid Use Disorder (OUD) and co-occurring mental disorders (COMD). (nih.gov)
  • Oral therapeutics for diabetes sit under the umbrella term of biologic therapeutics, which include large proteins, antibodies, hybrid fusion proteins, therapeutic peptides common tie, and antibody and drug conjugates. (azolifesciences.com)
  • Research has begun to explore RNAs potential to be used for therapeutic benefit, and unique challenges have occurred during drug discovery and implementation of RNA therapeutics. (wikipedia.org)
  • This information provides insight not only into the management of coronavirus diseases but also into the relative success of different approaches to identifying candidate therapeutics against an emerging disease. (nih.gov)
  • What Approaches Have Been Developed to Overcome the Permeability Barrier for Oral Therapeutics for Diabetes? (azolifesciences.com)
  • Our integrated model combines multiple R&D technology platforms - including Life Edit gene editing - and cGMP manufacturing to power the discovery and development of advanced therapeutics.Our ecosystem is designed to enhance speed, delivery, and probability of success to change patient lives. (biospace.com)
  • The 47,400 square foot facility, located at 351 Rouse Boulevard in The Navy Yard's Corporate Center, will house a state-of-the-art cGMP manufacturing facility designed to support the clinical development and initial commercialization of the Company's novel engineered immunotherapies for cancer. (areadevelopment.com)
  • ABL's portfolio of services includes feasibility studies, process and assay development, cGMP manufacturing, IND-enabling GLP safety, pharmacokinetic and efficacy studies, stability studies, and product release testing. (ablinc.com)
  • I believe that ImmunOs´ expertise in pioneering HLA-based therapeutics focusing on both oncology and immunology, led by IOS-1002, ImmunOs´ lead clinical candidate in oncology, is at the forefront of current research," said Dr. Constanze Guenther, Senior Vice President, CMC and Technical Development at ImmunOs. (wowktv.com)
  • Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec's oncology project EVT801. (checkorphan.org)
  • Upon exercising an option, the firm will pay Molecular Partners an option fee and take on responsibility for all subsequent development, manufacturing, and commercialization activities. (genengnews.com)
  • Acquisition of Sanifit is for the continued clinical development and commercialization of SNF472, a novel, first-in-class intravenously administered inhibitor of vascular calcification, for the treatment of CUA and PAD in patients with end-stage kidney disease. (menafn.com)
  • Prevail would lead all further development, manufacturing and commercialization of products incorporating the licensed capsids. (businesswire.com)
  • Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease patients with progressive vascular calcification disorders, and Inositec AG, a Swiss company, developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders. (menafn.com)
  • Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. (valleycentral.com)
  • This acquisition builds on years of hard work from the entire Inositec team and provides a strong foundation for improving outcomes for patients suffering from cardiovascular and vascular calcification disorders," said Mattias Ivarsson, Founder and Chief Executive Officer of Inositec, adding"Inositec's transition to a clinical-stage company represents an ideal time to partner with Vifor Pharma to accelerate the clinical development of INS-3001. (menafn.com)
  • Opioid Use Disorder (OUD) and co-occurring mental disorders (COMD) frequently are present in a single individual, and yet they take separate paths in the therapeutics development process https://www.nimh.nih.gov/health/topics/substance-use-and-mental-health . (nih.gov)
  • The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. (stockhouse.com)
  • advancing the development of Psilocybin-based therapeutics in various diseases and disorders. (stockhouse.com)
  • SONGDO, South Korea , April 22, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics Inc. announced the successful FDA IND approval of IMC-002 under a development and manufacturing agreement with Samsung Biologics since 2018. (prnewswire.com)
  • Dignify Therapeutics LLC, a pharmaceutical and medical device development company focused on restoring bladder and bowel control for people with spinal injury, multiple sclerosis, diabetes, and the elderly, was awarded the prestigious Blueprint Neurotherapeutics Network grant from the National Institutes of Health (NIH). (simonfoundation.org)
  • Established in 2016 as a joint venture company between Yuhan and Sorrento, ImmuneOncia leverages both companies' expertise in drug development and antibody engineering. (prnewswire.com)
  • ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and inflammatory diseases. (wowktv.com)
  • The Cystic Fibrosis Therapeutics Development Network is the largest CF clinical trials network in the world. (cff.org)
  • The two companies collaborated exceptionally well together during the whole development process including the IND evaluation period, allowing us to enter phase I clinical trials for IMC-002 much quicker. (prnewswire.com)
  • We are very impressed with the outstanding service Samsung Biologics provided in the full development scope - from cell line development, process development, preclinical and clinical manufacturing, and IND filing support," said Yun Jeong Song , CEO of ImmuneOncia. (prnewswire.com)
  • This 4-year award provides over $4 million in funding to support preclinical and clinical development of the Company's lead drug candidate, DTI-117, to treat bladder and bowel dysfunction. (simonfoundation.org)
  • Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. (drugdiscoverytrends.com)
  • You'll study subject-specific content in transitional medicine and therapeutics research. (ncl.ac.uk)
  • Course content changes periodically to reflect developments in the discipline, the requirements of external bodies and partners, and student feedback. (ncl.ac.uk)
  • The second deal takes the form of an exclusive discovery alliance through which the partners will collaborate on the design and development of DARPins against targets implicated in serious eye diseases. (genengnews.com)
  • Kazia and Evotec have also entered into a master services agreement, under which the two companies will collaborate closely on the further development of EVT801. (checkorphan.org)
  • Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the company's portfolio of innovative assets. (menafn.com)
  • Aptevo Therapeutics Inc (APVO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. (researchandmarkets.com)
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. (researchandmarkets.com)
  • We are honored both to receive this award and to continue our productive research project with the Foundation," stated Stuart W. Peltz, Ph.D., president and chief executive officer of PTC Therapeutics. (cff.org)
  • We appreciate the strong support from this group of investors and believe this capital will help propel Kronos through our upcoming period of clinical development," said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos. (techstartups.com)
  • We are encouraged by the data from our ongoing studies of STK-001, which continue to demonstrate favorable safety findings and reductions in seizure frequency among a highly refractory group of patients,' said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics. (yahoo.com)
  • Novartis' former chief medical officer John Tsai has returned to a senior position in biopharma, taking the role of chief executive of UK start-up Forcefield Therapeutics. (pharmaphorum.com)
  • The regulatory approvals in France and Austria will allow us to expand our footprint in Europe and are another important step forward for our ATH434 development program," said David Stamler, M.D., Chief Executive Officer, Alterity. (yahoo.com)
  • This presents exciting possibilities of drug development for small patient cohorts and eventually even for single patients. (ktla.com)
  • RNA Therapeutics: A New Paradigm for Drug Development? (mendelspod.com)
  • Has the pandemic unleashed the molecule of RNA to be the new future of drug development? (mendelspod.com)
  • Located in Durham, NC, members of Life Edit work closely with the ElevateBio Research and Development and BaseCamp manufacturing teams in Waltham, MA. (biospace.com)
  • This event has been organized to bring together the world's leading researchers and leaders in academia, industry, the non-profit sector and government to discuss the challenges and opportunities facing those engaged in the research and development of psychedelics for various health conditions with considerable unmet need. (pharmamanufacturing.com)
  • A zoliflodacina, um novo antibiótico oral, primeiro da classe e um dos únicos tratamentos em desenvolvimento para enfrentar a crescente ameaça da gonorreia multirresistente, entrará em ensaios decisivos graças a uma colaboração entre a Parceria Global para Pesquisa & Desenvolvimento em Antibióticos (GARDP, na sigla em inglês de Global Antibiotic Research and Development Partnership ), e Entasis Therapeutics. (dndi.org)
  • Army Medical Research and Development Command, Fort Detrick. (cdc.gov)
  • Individualized Therapeutics Development for Rare Diseases: The Current Ethical Landscape and Policy Responses. (cdc.gov)
  • Her breadth and depth of expertise in technical development, manufacturing and operations will be important for advancing our first-in-class pipeline of multi-functional immunotherapies to and through clinical development. (wowktv.com)
  • With this facility, we intend to deliver on the promise of messenger RNA therapeutics by developing transformative new medicines for a wide range of diseases, including many that are untreatable today. (areadevelopment.com)
  • Called GlycoPRIME, the system could lead to faster development of therapeutics and a new, modular way to make medicines on demand in resource-limited settings. (northwestern.edu)
  • The Company expects to have its novel lyophilized formulation of Bucillamine ready for production with a contract development manufacturing organization for clinical evaluation in 2024. (valleycentral.com)
  • Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services. (prnewswire.com)
  • This contract supports the NIH Biologics development projects for the NIH Blueprint Neurotherapeutics Network Biologics (BPN-Biologics) program, the NINDS Ultra-Rare Gene Therapy (URGenT) program, the Helping to End Addiction Long-term Pain Therapeutics Development Program (HEAL-PTDP), and other extramural or intramural NIH drug discovery and development programs. (ablinc.com)
  • A new treatment option is now available for patients suffering from agitation associated with schizophrenia or bipolar I or II disorder," said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. (globenewswire.com)
  • Evotec receives a small upfront payment as well as further payments for continued support progressing EVT801 into the clinic and beyond, e.g. for biomarker development and CMC. (checkorphan.org)
  • Molecular Partners could receive up to another $1.4 billion in aggregate development, regulatory, and sales milestones, plus tiered royalties on future product sales. (genengnews.com)
  • To date, a small number of therapeutics have already been authorized by regulatory agencies such as the Food and Drug Administration (FDA), while most remain under investigation. (nih.gov)
  • With a flawless regulatory approvals record, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide. (prnewswire.com)
  • The core of Defence Therapeutics platform is the ACCUM TM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. (pharmiweb.com)
  • Founded in 2017 by Angela Koehler, Christopher Wilfong, and Joshua Kazam, Kronos Bio is discovering and developing novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. (techstartups.com)
  • We are pleased to enter into a collaboration agreement with the world-renowned Sheba Medical Center for the development of ASO-based treatments for rare genetic diseases. (ktla.com)
  • This ascent will ultimately push the global sickle cell anemia therapeutics market into a positive development direction throughout the figure time frame (2016-2024). (medgadget.com)
  • However, the small number of patients for each disease has hindered development of dedicated treatments. (ktla.com)
  • Vifor Pharma is the ideal partner to take the development of Sanifit's calcification franchise forward and bring these novel treatments to patients as quickly as possible. (menafn.com)
  • These upcoming milestones, along with our strong financial foundation and late-stage programs, position BioXcel Therapeutics to deliver significant value to our shareholders while helping treat millions of patients. (globenewswire.com)